T
here’s no approved medication to treat patients with epilepsy so severe that they must be put into a coma to stop their seizures. An experimental drug from Sage Therapeutics (SAGE) aims to fill that void — if the key phase 3 clinical trial yields positive results. It’s expected to read out results within the next month.
It’ll be a pivotal moment not just for the patients, but for Sage and its investors. Here are seven things to know about Sage, which is based in Cambridge, Mass., and its epilepsy drug, brexanolone:
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
na
Evertime I think too much epilepsy attacks me,so I wanna know how to reduce stress and stop thinking too much.